Alignment Healthcare, Inc. — Healthcare Plans. Scored on the same transparent model behind the daily rankings.
★
ALHC
Alignment Healthcare, Inc. · Healthcare Plans
FCF$178mC
Rev+46.1%A
D/E1.25C
P/E69.5xC
PEG1.51C+
61.1Score
$13.20$2.7B
1Y Target$24.08Analyst consensus · 13 analysts
5Y Target$35.25Compound horizon
10Y Target$52.29Long-dated conviction
FCF$178mTTM · 06/26C
FCF $178m — modest; watch for margin expansion · TTM computed from 4 most-recent quarters (TTM · 06/26).
Rev+46.1%FY YoYA
Revenue +46.1% — hypergrowth, top decile · Computed from last two annual revenue figures (FY YoY).
D/E1.25C
D/E 1.25 — more levered than most Healthcare peers (≈90th pctile)
P/E69.5xC
P/E 69.5 — expensive vs Healthcare peers (≈90th pctile)
PEG1.51proxyC+
PEG 1.51 — modest premium; above fair value · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 61.1
Quality0.46
Growth1.00
Value0.50
Why this score
Diluting shareholders
Entry · Margin of safety
52-week rangeNear 52-week low
47% off the 12-month high
vs DCF fair value27% belowest. fair value ~$18
What the price assumes: free cash flow compounding at ~7% a year for the next decade — vs the ~25% a year our model projects from current growth and analyst estimates.
Model-generatedGenerated by the Bull Rankings model from this company's reported fundamentals, and checked against the figures shown above.
Why now
Healthcare Plans · market cap $2.7b. Down 47% from 52-week high of $25.12 — deep drawdown territory. Revenue growing +46% — in hypergrowth territory. 13 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $24.08 (implying +82% upside).
Moat
ROE 20% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk
Trailing P/E 69.5x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Down 47% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Net margin 0.9% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Horizon
1-3 yr $24.08 (13-analyst consensus) — fundamentals + valuation re-rating. 5 yr $35.25 at ~22% CAGR — compounding case rests on the competitive position widening. 10 yr $52.29 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
ALHC vs the Top Picks average
Pillar
ALHC
Book avg
Diff
Quality
0.46
0.84
-0.39
Growth
1.00
0.92
+0.08
Value
0.50
0.75
-0.25
Averaged across the 30 names in today's Top Picks (mean score 82.9). A name can beat these averages and still be absent from the book — it also applies concentration limits.
Score history · ALHC
Trend
+7.1 over 39 daily scores
From 54.0 (Jun 22) → 61.1 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · ALHC
$
%
%
Shares to buy
151
Position size
$1,993
4.0% of portfolio
Stop price
$9.90
25% below $13.20
$ at risk if stopped
$498.30
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Alignment Healthcare, Inc. (ALHC): score, valuation & FAQ
Alignment Healthcare, Inc. (ALHC) is a Healthcare Plans company that scores 61.1 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A). On valuation, ALHC sits about 27% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 7% annual free-cash-flow growth over the next decade.
Is ALHC a good stock to buy?
Bull Rankings scores ALHC 61.1 out of 100 on its quality-growth model, which is a middling reading. That is driven by Rev (A). A score is a quantitative screen of Alignment Healthcare, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does ALHC score 61.1 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). ALHC earns its highest marks on Rev (A). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is ALHC overvalued or undervalued?
Based on $13.20, ALHC sits about 27% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 7% annual free-cash-flow growth over the next decade. It trades at a 69.5x× P/E (graded C). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in ALHC?
Trailing P/E 69.5x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Down 47% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Net margin 0.9% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.